1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.nurt.2008.10.035" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.nurt.2008.10.035</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
141-151
Issue
1
Volume
6
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Dual-Target-Directed Drugs that Block Monoamine Oxidase B and Adenosine A(2A) Receptors for Parkinson's Disease
Publisher
An entity responsible for making the resource available
Neurotherapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-01
Subject
The topic of the resource
adenosine A(2A) receptor; antagonist; caffeine; dopaminergic neurotoxicity; dual-target-directed drug; human-brain; inhibition; istradefylline; l-dopa; mao-b; monoamine-oxidase-b; motor complications; Neurosciences & Neurology; parkinsons-disease; Pharmacology & Pharmacy; rat model; substantia-nigra
Creator
An entity primarily responsible for making the resource
Petzer J P; Castagnoli N; Schwarzschild M A; Chen J F; Van der Schyf C J
Description
An account of the resource
Inadequacies of the current pharmacotherapies to treat Parkinson's disease (PD) have prompted efforts to identify novel drug targets. The adenosine A(2A) receptor is one such target. Antagonists of this receptor (A(2A) antagonists) are considered promising agents for the symptomatic treatment of PD. Evidence suggests that A(2A) antagonists may also have neuroprotective properties that may prevent the development of the dyskinesia that often complicates levodopa treatment. Because the therapeutic benefits of A(2A) antagonists are additive to that of dopamine replacement therapy, it may be possible to reduce the dose of the dopaminergic drugs and therefore the occurrence of side effects. Inhibitors of monoamine oxidase (MAO)-B also are considered useful tools for the treatment of PD. When used in combination with levodopa, inhibitors of MAO-B may enhance the elevation of dopamine levels after levodopa treatment, particularly when used in early stages of the disease when dopamine production may not be so severely compromised. Furthermore, MAO-B inhibitors may also possess neuroprotective properties in part by reducing the damaging effect of dopamine turnover in the brain. These effects of MAO-B inhibitors are especially relevant when considering that the brain shows an age-related increase in MAO-B activity. Based on these observations, dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A(2A) receptors, may have value in the management of PD. This review summarizes recent efforts to develop such dual-acting drugs using caffeine as the lead compound.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.nurt.2008.10.035" target="_blank" rel="noreferrer noopener">10.1016/j.nurt.2008.10.035</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2009
adenosine A(2A) receptor
Antagonist
caffeine
Castagnoli N
Chen J F
dopaminergic neurotoxicity
dual-target-directed drug
human-brain
inhibition
istradefylline
Journal Article
l-dopa
mao-b
monoamine-oxidase-b
motor complications
Neurosciences & Neurology
Neurotherapeutics
parkinsons-disease
Petzer J P
Pharmacology & Pharmacy
rat model
Schwarzschild M A
substantia-nigra
Van der Schyf C J